Compare PNR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | CYTK |
|---|---|---|
| Founded | 1966 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 10.4B |
| IPO Year | 2003 | 2004 |
| Metric | PNR | CYTK |
|---|---|---|
| Price | $75.07 | $78.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | ★ $109.73 | $89.26 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 5.88 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $4.24 | $7.37 |
| Revenue Next Year | $4.82 | $310.19 |
| P/E Ratio | $71.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $69.93 | $31.99 |
| 52 Week High | $113.95 | $80.20 |
| Indicator | PNR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 63.90 |
| Support Level | $70.35 | $59.07 |
| Resistance Level | $75.66 | $79.66 |
| Average True Range (ATR) | 1.70 | 3.20 |
| MACD | 0.69 | 0.56 |
| Stochastic Oscillator | 66.02 | 89.87 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.